Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation
Amir T. Fathi(University of Southern California), Mark J. Levis(Sidney Kimmel Cancer Center), Andrew M. Brunner(Harvard University), Kaitlyn Fishman(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Meghan Burke(Harvard University), Kristin McGregor(Harvard University), Jenna A. Moran(Harvard University), Tanya T. Behnan(Harvard University), Karen K. Ballen(University of Virginia Health System), Jessica M. Caverly Rae(Harvard University), David Avigan(Beth Israel Deaconess Medical Center), Christine Connolly(Massachusetts General Hospital), Gabriela Hobbs(Massachusetts General Hospital), Daniela Hernandez(Johns Hopkins University), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Traci M. Blonquist(Harvard University), Meghan Bergeron(Harvard University), Ashley Perry(Harvard University), Tina T. Som(Harvard University), Emma Logan(Beth Israel Deaconess Medical Center), Aura Y. Ramos(Harvard University), Julia Foster(Harvard University), Donna Neuberg(Otsuka (Japan)), Christelle Joseph(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 31